|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:temple
|
|
gptkbp:activities
|
inhibits ADP-induced platelet aggregation
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:ticagrelor
|
|
gptkbp:class
|
antiplatelet agent
|
|
gptkbp:clinical_trial
|
Phase III
stenting procedures
percutaneous coronary intervention
primary prevention
secondary prevention
|
|
gptkbp:contraindication
|
active bleeding
severe renal impairment
severe liver impairment
history of intracranial hemorrhage
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:has_ability
|
60 mg
90 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Brilinta
|
|
gptkbp:indication
|
gptkb:hospital
gptkb:unstable_angina
acute coronary syndrome
|
|
gptkbp:ingredients
|
gptkb:ticagrelor
|
|
gptkbp:interacts_with
|
other anticoagulants
NSAI Ds
SSR Is
|
|
gptkbp:invention
|
2026
|
|
gptkbp:is_monitored_by
|
hemoglobin levels
platelet function
|
|
gptkbp:is_used_for
|
preventing blood clots
|
|
gptkbp:lifespan
|
7 hours
|
|
gptkbp:manufacturer
|
gptkb:temple
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
|
|
gptkbp:metabolism
|
CY P3 A4
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
adults
elderly
|
|
gptkbp:previous_name
|
gptkb:theorem
|
|
gptkbp:provides_information_on
|
gptkb:European_Society_of_Cardiology
gptkb:American_College_of_Cardiology
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:rounds
|
hepatic
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
bruising
gastrointestinal bleeding
vomiting
bleeding
palpitations
dyspnea
|
|
gptkbp:storage
|
room temperature
|